Epilepsy Treatment Market By Treatment Type (Surgical {Resective Surgery, Disconnective Surgery, Lesionectomy} Non-Surgicals, Medications, Deviices {Vagus Nerve Stimulation (VNS), Responsive Neurostimulation (RNS), Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS)} Other Therapies), By Epilepsy (Focal Epilepsy, Generalized Epilepsy, Unknown Onset Epilepsy), By Route of Administration (Oral, Intravenous, Transdermal, Intranasal, Other), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics), and By End-user (Hospitals, Neurology Clinics, Home Care Settings, Research Institutions), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Epilepsy Treatment market accounted for USD 8.35 Billion in 2024 and is expected to reach USD 15.36 Billion by 2035, growing at a CAGR of around 5.7% between 2025 and 2035. The epilepsy treatment spans a range of therapies aimed at the control of the disease via antiepileptic drugs, which are first-line agents for the management of this disease. While some of the older AEDs such as phenytoin and carbamazepine and newer AEDs like levetiracetam are still used very widely, there is always hope for those patients whose conditions cause severe incapacitating seizures or complete failure of pharmacological management, for whom surgical approaches such as resective surgery or responsive neurostimulation can stand in as an alternative option. Vagus nerve stimulators, ketogenic diet, and many more are the devices and diets available to epilepsy patients. Newer ones being researched, such as gene therapy and cannabinoids, will also play a role in the future market. With growing awareness of this disease and new treatments being developed, probably the market for management strategies will keep on going.

Report Scope:

Market Dynamics

• Increasing Prevalence of Epilepsy and the Need for Effective Treatments

The incidence of epilepsy is on the increase globally due to a combination of causes. Increased population size and ageing of the population elevate the count of victims and better sensitization and diagnoses greatly contribute to reported rates in developing areas. Neurocysticercosis has greatly boosted infectious causes of epilepsy in those low-income nations, besides physical trauma resulting from traffic and interpersonal violence. The socioeconomic stressors of poverty and low access to health care make matters worse, especially in developing countries.

Currently, around 50 million people are affected by epilepsy; WHO revealed that the prevalence lies between 10-15 cases per 1,000 population in low and middle-income countries whereas 4 to 10 cases are present in high-income countries. Nearly 1 out of 26 people has had a seizure or will have a seizure during his/her lifetime, and of those, approximately 80% live in developing countries where treatment is unavailable.

• Advancements in Epilepsy Management Through Emerging Technologies

As epilepsy afflicts nearly 50 million around the world and continues to rise in incidence, better management approaches are urgently needed. This overview describes advances in wearable devices and neurostimulation techniques that are also becoming rapidly available for improved results of these conditions, from high-fidelity detection of seizures up to 90 percent with wearable devices to a full half reduction in seizures with certain individuals on responsive neurostimulation (RNS).

According to the Epilepsy Foundation, a survey revealed that 78% of patients are keen on using wearable technology for monitoring. It is further reported that the wearable health technology market is going to reach $60 billion in 2023, evidence of the ever-growing demand of the consumer for effective solutions in epilepsy management. Such innovations promise to bring quality life to millions suffering from epilepsy.

• Cost Challenges in Accessing Advanced Epilepsy Treatments and Medications

Accessing advanced epilepsy treatments poses significant financial barriers for many patients. Insurance coverage often falls short, with 45% of patients reporting financial barriers that affect their ability to afford medications, according to the National Epilepsy Foundation. Low and middle-income countries have a relatively limited healthcare budget, and about 80 percent of people with epilepsy have only limited access to any treatments.

The WHO also highlights that the average annual health expenditure per capita in those regions is often less than $100, which makes matters worse in terms of affordability. Even though a few of the antiepileptic drugs are available in generic forms, most of the newer ones are not, which in turn increases their costs. Additionally, social stigma and employment discrimination against epilepsy patients can be attributed to lower incomes and other negative consequences preventing them from paying for treatment. Surveys showed that 25% of patients failed to take medications due to cost. Also, one study reports that failure to take doses places these patients 60% more at risk for seizures. Overcoming these financial barriers should ensure therapies become accessible to clients with epilepsy for a better quality of life.

• Developing Targeted Treatments for Pediatric Epilepsy

The development of targeted treatments for pediatric epilepsy presents significant opportunities, given that the CDC estimates around 470,000 children in the U.S. have epilepsy, making it the most common childhood brain disorder. This condition often presents with varying seizure profiles and responses to medication differently than adults, therefore holding a huge niche for special treatments. New advances in genetics are driving precision medicine. Researchers now estimate that close to 30% of childhood epilepsy cases can be identified with specific genetic causes.

At the same time, there is an increasing requirement for pediatric-specific formulations of AEDs, and many available medications are not suitable for children. There is an increasing demand for quality life treatments from families, and a related study indicates that active participation by the patient in treatment decisions helps with adherence. According to the WHO, fully appropriate treatment is administered to only 25% of children in low-income countries, providing significant market growth opportunities and better patient outcomes for children suffering from epilepsy. A healthcare provider and pharmaceutical company can significantly improve young patients' quality of life through such exploitation.

• Advancements in Medical Technology and Increased Awareness of Neurological Conditions

The recent advancement of medical technology and increased awareness of neurological conditions offer an opportunity to improve the delivery of care to patients. Newer tools, for example, wearable devices, allow detection rates of seizures as high as 90% and keep improving patient safety and management. Increased cases of telemedicine delivery have also allowed access to healthcare to many patients, especially during the COVID-19 pandemic, which caused a 300% increase in neurology telehealth visits because this technique allowed the underserved people to get the much-needed support at the right time.

Campaigns like the Epilepsy Foundation-sponsored promise to raise public awareness have encouraged 78% more people to come in to diagnose themselves or seek treatments besides these efforts that are creating greater awareness of epilepsy among the general public. Big data integrated with AI informs personalized approaches to treatment, and NIH funding in increasing trends is being allocated toward new and novel therapies.

With 1 in 26 likely to develop epilepsy and 80% of those with neurological disorders living in low- and middle-income countries, the urgent need for effective management solutions follows logically. Healthcare providers can improve the quality of life of those with neurological disorders significantly through these advances and awareness.

Industry Experts Opinion

"Improving seizure control, especially of the most severe seizures, could mitigate neurodevelopmental delay, improve quality of life, minimize polypharmacy, and reduce injury and premature death, namely sudden unexpected death in epilepsy (SUDEP),"

• Dr. Kelly Knupp, pediatric neurologist, Associate Professor of Pediatrics and Neurology, University of Colorado.

"For people and caregivers impacted by DEEs such as DS and LGS, the ability to effectively manage seizures is critical. These findings reinforce the potential of FINTEPLA in reducing seizure frequency among patients with DEEs,"

• Rebecca Burns, PhD, Medical Strategy Lead, Epilepsy and Rare Syndromes, UCB.

Segment Analysis

Based on the treatment type, the market for epilepsy treatment has been classified into surgical and non-surgical options based on the type of treatment. Surgical treatment market further sub categorizes into three, which are resective surgery, disconnective surgery, and lesionectomy. The non-surgical treatment market is comprised of medicines, devices, VNS, RNS, DBS, TMS, and other therapies. This classification represents all the different approaches used in the management of epilepsy, cut out to represent the various needs of the patients.

Based on epilepsy type, the market has been classified into three types based on the type of epilepsy, focal epilepsy, generalized epilepsy, and unknown onset epilepsy. Furthermore, the market for focal epilepsy has been categorized into treatments targeted at particular areas of the brain including medication as well as surgery, the latter tailored to the focal nature of the seizures. The generalized epilepsy market includes approaches that address widespread seizure activity, primarily through various antiepileptic medications. The unknown onset epilepsy market focuses on strategies that combine different therapies to manage the unpredictability of seizures. This classification highlights the diverse treatment options available, ensuring that patient needs are effectively addressed.

Regional Analysis

The North American epilepsy treatment market has a good and high-level health infrastructure and high patient awareness. In the U.S., it is estimated to have a prevalence for epilepsy of 5 to 10 per 1,000; the incidence rate was about 50 per 100,000 people per year, which manifested in children under five and the elderly. Active epilepsy among adult's accounts for an estimated 2,865,000 people, many of whom were reported with only a high school diploma or GED or lower in 2021. Healthcare expenditures specifically related to epilepsy amounted to $24.5 billion in 2019. Increased investment by the NIH has encouraged an increase in innovative treatment modalities. Campaigns have changed the nature of early diagnosis and treatment-seeking behavior. Eliminating stigma and ensuring access to care would go a long way in collaboration between healthcare providers and advocacy organizations. Its cost of treatment and inequities in access to care remain the biggest challenges. In general, the market is likely to continue growing with technological advances and improved patient care results.

The Asia Pacific epilepsy treatment market is rapidly evolving due to a combination of rising prevalence rates of epilepsy, increasing government initiatives aimed at improving mental health care, and advancements in medical technology. More than 23 million patients suffer from epilepsy across the Asia region, which accounts for 50% of the world's patient population. In 2019, South Asia led in the number of people diagnosed with idiopathic epilepsy globally. However, the cost of treatment for epilepsy in Asia is relatively high in comparison with the GDP of the region, for instance, the direct cost over six months in China is estimated at USD 625, while in India, it is USD 344 yearly. The cost is much higher in Western countries, at USD 1, 376 in Italy and USD 2, 384 in France. It varies depending on local areas, as people residing in urban areas can avail of advanced treatments, while diagnosis and management are difficult in rural populations. Despite existing barriers, the Asia Pacific market is very prospective in terms of expansion and improvement in patient care.

Competitive Landscape

Leading players in the market are Pfizer Inc., Novartis AG, Abbott, Neurelis Inc., and GSK plc, though the market of epilepsy treatment is highly impacted by the following: Pfizer possesses a robust portfolio of antiepileptics and is aggressively collaborating with technology companies to further their research in the fields of drug delivery and patient monitoring. Novartis has received accolades for innovative therapeutic drugs and has recently forged strategic collaboration deals to produce new versions of the formulations for its existing products. Abbott has focused its efforts on neuromodulation devices and further enriched itself by acquiring St. Jude Medical to enhance the scope of services in the space of epilepsy. Neurelis Inc. is dedicated to epilepsy solutions, particularly with its lead product, VALTOCO and also has collaborations for strategic positioning and market and distribution activity. GSK plc is focused on new antiepileptic drugs and successful new drug candidate introductions by investing in research and development through collaboration with academic partners. These companies not only expand the drugs for treatments but also improve the care of patients in terms of new therapies within the epilepsy market.

Epilepsy Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• On June 24, 2024, EpilepsyGTx announced it raised $10 million in seed funding to develop gene therapies for focal refractory epilepsy. The financing was led by the UCL Technology Fund, with participation from Health Technology Holding, supporting the company's innovative treatment efforts.
• On May, 2023, FDA approved a new drug application for Lacosamide (Motpoly XR) extended-release capsules, 100 mg, 150 mg, and 200 mg for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
• On March 2022, FDA has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.

Report Coverage:

By Treatment Type

• Surgical
  • Resective Surgery
  • Disconnective Surgery
  • Lesionectomy
• Non- Surgical
  • Medications
  • Devices
    • Vagus Nerve Stimulation (VNS)
    • Responsive Neurostimulation (RNS)
    • Deep Brain Stimulation (DBS)
    • Transcranial Magnetic Stimulation (TMS)
  • Other Therapies

By Epilepsy

• Focal Epilepsy
• Generalized Epilepsy
• Unknown Onset Epilepsy

By Route of Administration

• Oral
• Intravenous
• Transdermal
• Intranasal
• Other

By Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

By End-user

• Hospitals
• Neurology Clinics
• Home Care Settings
• Research Institutions

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Pfizer Inc.
• Novartis AG
• Abbott
• Neurelis Inc.
• GSK plc
• Johnson & Johnson Services Inc.
• Teva Pharmaceutical Industries Ltd.
• Sumitomo Dainippon Pharma Co. Ltd
• Bausch Health Companies Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• UCB S.A.
• Marinus Pharmaceuticals Inc.
• Eisai Co. Ltd
• H. Lundbeck A/S
• Supernus Pharmaceuticals Inc.
• DAIICHI SANKYO COMPANY LIMITED

Frequently Asked Questions (FAQs)